Radiation vs. monitoring after surgery for high-risk ACC
Part of Cancer, Hormones & metabolism clinical trials.
This study compares the use of radiation therapy after surgery versus simply monitoring for patients with high-risk adrenocortical carcinoma (ACC) that hasn't spread. The goal is to see if radiation helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had surgery to remove your adrenocortical carcinoma (ACC) with the goal of curing it.
- Your tumor shows at least one high-risk feature (like a high Ki-67 index, stage 3, positive margin, or high grade).
- You have not had radiation to your abdomen or pelvis before.
- You are not pregnant or breastfeeding, and are willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether radiation therapy to the pelvis after prostate removal helps men whose cancer was found in nearby lymph nodes. The goal is to prevent cancer from coming back and improve survival.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
This trial tests whether giving radiation before surgery helps people with adrenal cancer that has come back after previous treatment. It aims to see if this approach can improve outcomes for patients who can have surgery at the NIH.
This trial compares two strategies after surgery for a type of skin cancer (cutaneous squamous cell carcinoma) that has a high chance of coming back. One strategy gives radiation therapy to the area, while the other just watches and checks for any signs of recurrence. The goal is to see if radiation can prevent the cancer from returning.
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
This study looks at whether giving mitotane after surgery (and possibly adding cisplatin/etoposide chemotherapy) helps prevent adrenal cancer from coming back. It is for people with stage I–III adrenal cortical cancer who have a high risk of relapse after their tumor was removed.
Hear when a new Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.